• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Pfizer Ltd.
    28 Aug 2025
    5227.00
    1.15%
    Why getting Covid-19 vaccine is likely to be more complicated this year?
    Business Line
    The US Food and Drug Administration has OK'd new shots from Pfizer, Moderna and Novavax, but the approvals came with some new caveats
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. has gained 28.57% in the last 6 Months
    logo
    SMS Pharmaceuticals Ltd.
    28 Aug 2025
    291.27
    -3.09%
    SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report
    Business Standard
    SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA
    Copy LinkShare onShare on Share on Share on
    SMS Pharmaceuticals Ltd. has gained 23.29% in the last 1 Week
    logo
    Cipla Ltd.
    27 Aug 2025
    1574.60
    0.88%
    Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US
    Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US
    NDTV Profit
    The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    Cipla recalls over 20k packs of inhalation drug in US
    Business Line | 27 Aug 2025
    logo
    Sai Life Science Ltd.
    26 Aug 2025
    872.70
    0.45%
    Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale; Societe Generale, Goldman Sachs Acquire
    Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale; Societe Generale, Goldman Sachs Acquire
    NDTV Profit
    IIFL Capital Services Ltd., Kotak Securities Ltd. and Jefferies India Pvt. were the bookrunners for the deal.
    Copy LinkShare onShare on Share on Share on
    Sai Life Science Ltd. is trading above all available SMAs
    Sai Life Sciences slips 5% on heavy volumes; should you buy, sell or hold?
    Business Standard | 26 Aug 2025 1 more
    Sai Life Sciences Block Deal: TPG Likely To Exit Via Rs 2,640-Crore Stake Sale
    NDTV Profit | 25 Aug 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    26 Aug 2025
    Acquisition
    1316.70
    1.04%
    Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access
    Business Standard
    Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr Reddy's launches drug for treatment of chronic constipation
    Business Line | 26 Aug 2025 1 more
    Dr Reddy's launches novel drug for chronic constipation management
    Business Standard | 26 Aug 2025
    logo
    Aurobindo Pharma Ltd.
    26 Aug 2025
    1094.40
    -1.33%
    Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys
    Business Standard
    CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Indoco Remedies Ltd.
    26 Aug 2025
    299.05
    -3.09%
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price
    NDTV Profit
    Nirmal Bang values the company at 11x Jul-27E EV/Ebitda and maintain Hold rating on Indoco Remedies, resulting in a target price of Rs 310.
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd.'s price crossed below 50Day SMA today
    logo
    Sun Pharmaceutical Industries Ltd.
    26 Aug 2025
    1616.60
    0.43%
    Sun Pharma shares slip 3% after BofA downgrade on premium valuations
    Sun Pharma shares slip 3% after BofA downgrade on premium valuations
    Economic Times
    Bank of America downgraded Sun Pharma stock to underperform' from neutral', citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 30 day SMA of 1613.0
    logo
    Senores Pharmaceuticals Ltd.
    25 Aug 2025
    Insider Trades
    689.90
    -2.61%
    Broker's call: Senores Pharma (Buy)
    Business Line
    Choice International
    Copy LinkShare onShare on Share on Share on
    Senores Pharmaceuticals Ltd. has gained 76.45% in the last 1 Year
    logo
    Akums Drugs & Pharmaceuticals Ltd.
    25 Aug 2025
    462.00
    0.51%
    Akums Drugs announces JV to set up manufacturing facility in Zambia
    Business Standard
    Akums will hold 51% in its joint venture with the Zambian government to set up a pharma manufacturing facility, marking its first overseas plant and Africa expansion
    Copy LinkShare onShare on Share on Share on
    Akums Drugs & Pharma.. has an average target of 655.00 from 1 broker.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd